Editorial Policies



Folia Medica Indonesiana aims to publish scientific articles in medical sciences, with focus on basic and clinical medicine, public health as well as health sciences. We accept original research report, systematic review and/ or meta-analysis also case series with scoping review in the discussion. The focus of all manuscripts submitted to Folia Medica Indonesiana should be aimed to contribute positively to the body of knowledge in medicine and health sciences.

The scope of this journal is, but not limited to, general medicine, specialist medicine, tropical and infectious diseases, also non-communicable diseases, with priority publication for cases that occur in Indonesia. Manuscripts describing research in animals can be considered eligible as long as the results have a clear correlation and/ or impact on human health.

Authors may contact the journal via email in advance to inquire about whether their research topic is suitable for consideration by Folia Medica Indonesiana.




Checked Open Submissions Checked Indexed CheckedPeer-Reviewed


Checked Open Submissions Checked Indexed CheckedPeer-Reviewed


Checked Open Submissions Checked Indexed Checked Peer-Reviewed


All articles for Folia Medica Indonesiana are posted online 4 times a year in March, June, September, and December. All articles will be assigned a Digital Object Identifier (DOI) number whereby they become searchable and citable without delay.



Folia Medica Indonesiana is published Open Access under a Creative Commons CC BY-NC-SA 4.0 license. For more information see the copyright section.

Articles are published immediately upon the final corrections of the master proof having been made. All articles are assigned a Digital Object Identifier (DOI). 

Folia Medica Indonesiana is accessible via the journal’s website at https://e-journal.unair.ac.id/FMI as well as via international search engines such as Google Scholar and DOAJ



This journal utilizes the Public Knowledge Project Private LOCKSS Network (PKP PLN) and CLOCKSS systems to create a distributed archiving system among participating libraries and permits those libraries to create permanent archives of the journal for purposes of preservation and restoration.



Every article submitted to Folia Medica Indonesiana shall use reference management software, e.g., EndNote® or Mendeley.



Folia Medica Indonesiana follows ethical standards set by the Committee on Publication Ethics (COPE), the World Association of Medical Editors (WAME), and the Initiative for Open Citations (I4OC). Folia Medica Indonesiana aims to uphold ethical standards and safeguard participants’ rights, privacy, and welfare; this also applies to the study using animal models. Universitas Airlangga, as the publisher, upholds these standards and ensures editorial decisions are unbiased. A submitted manuscript undergoes rigorous double-blind peer-review, which means both author and peer-reviewer are blinded to each other. Any form of plagiarism is not accepted, and Folia Medica Indonesiana checks all submitted papers for similarity using https://turnitin.com with an acceptance score less than 20%.

For Editor

  • Editor is responsible for the content published and must follow strict standards and journal policies. Editor has the authority to accept, reject, or request changes to manuscripts, prioritizing timely review and publication.
  • Editor evaluates manuscript originality and ethical considerations. They ensure a fair peer review process, selecting unbiased reviewers without conflict of interests. Peer review procedures are communicated clearly to authors.
  • Editor makes unbiased decisions based on the content, avoiding biases related to personal attributes. Editor ensures fairness and equity throughout the publication process.
  • Editor maintains the confidentiality of manuscripts, sharing information only with authorized reviewers. Confidential discussions are kept private, except in exceptional cases.
  • Editor must ensure that the aims and scope are in line with Folia Medica Indonesiana and ensure proper citations.
  • Editor upholds content integrity by addressing misconduct. Editor obtains consent before using unpublished materials from submitted manuscripts. Editor avoids decisions involving conflict of interests.
  • The final decision and publication are decided by the Editorial Board; the author may appeal this decision, although the Editor-in-Chief will make the final decision on the manuscript.

For Reviewer

  • Manuscript undergoes a double-blind peer-review process, which means both author and peer-reviewer are blinded to each other, ensuring the anonymity of author and peer-reviewer for an unbiased assessment.
  • Peer-reviewer helps the editor make objective decisions and helps the author improve the manuscript's content quality.
  • Manuscript and related information should be kept confidential and not shared without authorization.
  • Peer-reviewer must provide clear opinions supported by evidence and give a problem solution accordingly. Peer-reviewer helps the editor check the originality of the manuscript and ensure that it adheres to ethical and scientific methods, presents comprehensive and interpretable results, and also reviews for correct and standard technical terms.
  • Peer-reviewer must inform the editors if finding out about significant similarities with other submitted and/ or published papers.
  • Peer-reviewer must maintain confidentiality and avoid any conflict of interests.
  • Peer-reviewer should provide timely feedback and notify about any delays to prevent prolonged processes that might cause any drawbacks.

 For Author

  • Author must submit the manuscript via online submission and make sure that the manuscript follows the guidelines for authors.
  • Author must have completed and submitted all requirements on the checklist.
  • Author must ensure that no academic disintegrity and/ or ethical misconduct occurred during the study and follow the below checklist according to your study type:

(for a qualitative study: COREQ, ENTREQ, GRADE-CERQual, SRQR; for a randomized controlled trial: CONSORT; for reporting data from e-survey: CHEERIES; for a study using survey data: CROSS; for reporting public or patient involvement: GRIPP2; for a systematic-review: PRISMA; for a scoping review: PRISMA-ScR; for an observational study in epidemiology: STROBE; for reporting a population health and policy intervention: TIDieR-PHP; for a prediction model development: TRIPOD; for systematic reviews and meta-analyses using transparent reporting of multivariable prediction models for individual prognosis or diagnosis: TRIPOD-SRMA; for a case report: CARE).

In a randomized controlled trial, the author must register the clinical trial in a publicly accessible registry before recruiting participants. The registration should provide comprehensive trial details and include a unique identification number. Timely reporting of trial results, regardless of the outcome, is mandatory. Author must provide proof of trial registration during manuscript submission, and adherence to these guidelines ensures transparency and ethical conduct in our journal's published trials, promoting research integrity and accurate reporting of results. Author must ensure that the recruitment is voluntary and unbiased, and research protocols must be approved by an ethical review committee. Author must ensure that the adverse event is reported and mitigated. Community engagement is crucial for culturally sensitive studies.

  • Author must obtain informed consent for publication that explains the study's purpose, procedures, risks, benefits, confidentiality, and data usage.
  • Author of the original research report must submit an ethical clearance from the authority where the study is conducted and state the date and number of the ethical clearance. All studies in humans must follow ethical values as stated by the World Association of Medical Editors (WAME).
  • Author must protect the anonymity of participants and remove identifying information from research data.
  • Author must ensure that vulnerable populations (e.g., children, pregnant women, prisoners) require a risk-benefit analysis, informed consent from authorized representatives, and protection of privacy. It is advisable to always follow the points stated by the World Association of Medical Editors (WAME).
  • Author must ensure that the study using animal models adheres to the Replacement, Reduction, and Refinement (3Rs) principles for animal subjects and follows the ARRIVE
  • Author should provide raw data upon request for editorial review and/ or post-publication.
  • Author must present truthful and objective findings with clear method descriptions for replication and avoidance of fraudulent statements.
  • Author must meet the publication criteria, avoid plagiarism, and properly acknowledge sources.
  • Author should avoid duplicating or redundant manuscripts and identify multiple publications from the same research project.
  • Author must give proper acknowledgment of data sources and influential publications.
  • Author should acknowledge substantial contributors as co-authors and others in the acknowledgment section with the co-authors' consent.
  • Author should disclose funding sources and conflict of interests.
  • Author should be responsible for promptly notifying editors of significant errors and collaborating to rectify them.
  • Author must actively engage in the peer-review process and address reviewers' comments thoroughly. Adherence to these guidelines ensures ethical publication practices and upholds research integrity.
  • Author must complete and upload all documents required that can be downloaded here.



Papers submitted to Folia Medica Indonesiana are subject to rigorous peer review so as to ensure that the research published is 'good science'.

Manuscripts are sent out for review electronically, and all correspondence takes place via e-mail. Although the peer review process is accelerated by the use of electronic communication, traditional, high-quality peer-review standards are applied to all manuscripts submitted to the journal.

Folia Medica Indonesiana apply a double blind peer-review process, which means both the author(s) and the peer-reviewer(s) keep their anonymity. Authors are not told who reviewed their submitted manuscript, and vice versa.

Peer reviewers are asked to give their opinion on a number of issues pertinent to the scientific and formal aspects of a paper, and to judge the papers on grounds of originality and urgency. All relevant information will be forwarded to the author(s).

Peer reviewers will have six possible options, for each article:

  1. Accept Submission (i.e., no need for any revision)
  2. Revisions Required (i.e., accepted if the author makes the requested revisions)
  3. Resubmit for Review (i.e., accepted or rejected after revisions have been made - paper will be sent out for another peer review round)
  4. Resubmit elsewhere (i.e., if the manuscript is better suited for another journal)
  5. Decline Submission (i.e., if the manuscript is substandard)
  6. See Comments (i.e., if the reviewer cannot choose from any of the above)

In addition, papers may be rejected directly by the Editor-in-Chief if judged to be out of scope or if scientifically or formally sub-standard.

When asking for revisions, reviewers have two possible goals: to ask authors to tighten their arguments based on existing data or to identify areas where more data are needed. Even formal revision may be required if the language or style is sub-standard. The whole process will take approximately 6-10 weeks.



The article processing charge for publication in Folia Medica Indonesiana is IDR 1.5 Million. Payment is due after the manuscript is accepted for publication in the journal. The journal does not require any submission charge.

Waiver Policy

We will consider all requests for discretionary APC waivers by researchers who are not eligible for the above. Please state your request for a discretionary waiver before submitting your manuscript by email to the APC team at fmi@journal.unair.ac.id.

Please include supporting evidence for why a waiver would be necessary for your circumstances. Your request should be details of:

  1. The affiliation and country of residence of all authors;
  2. Details of where the research was conducted; and
  3. Confirmation of all research grant funding received.
If you have already accepted a discounted price offered to you at the time of submission, please be aware that this is the maximum discount and we are unable to help you further.
Authors who receive the support of, or are employed by, a commercial organization (e.g., a pharmaceutical company) will not be liable to receive this discounted price. They will be asked to pay the full advertised price in effect at the time of submission.
Discounts may not be combined and where multiple discounts are available the one most favorable to the authors will apply.
Discounts can be determined by journal managers only if the authors have already submitted their waiver request through fmi@journal.unair.ac.id.

The waiver request form can be downloaded here.



Folia Medica Indonesiana does not tolerate any type of plagiarism. The editors of Folia Medica Indonesiana will screen all submitted manuscripts for plagiarism using the Turnitin Similarity checker. A similarity of more than 20% is not acceptable. Any manuscript that does not meet this requirement at the first screening should be revised by its authors before being re-submitted accordingly.



Folia Medica Indonesiana is now under cooperation of Unit of Journal Consortium and Folia Medica Indonesiana (UKJF), Faculty of Medicine, Universitas Airlangga. The information can be accessed through an external link at https://ukjf.fk.unair.ac.id/.



Folia Medica Indonesiana allows authors to deposit all versions of their work. This policy sets out the ways in which authors of Folia Medica Indonesiana can self-archive versions of their work in their own web pages, institutional web pages, and another repository. Further explanation can be seen in the table below.

Article Version Personal Website

Institutional or Non-Commercial Subject-Based Repository

Commercial Platforms and Social Media
Author Original Version (AOV) At any time At any time At any time
Accepted Manuscript (AM) At any time At any time At any time
Version of Record (VOR) At any time At any time At any time